Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM: the USA, France, ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. ACR ...

Please provide your email address to receive an email when new articles are posted on . Lupus nephritis (LN) is a serious and potentially life-threatening complication of systemic lupus erythematosus ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...

Urinary afamin and an immune biomarker model both show potential for distinguishing lupus nephritis. Urinary afamin, circulating immune cell ratios, and antimitochondrial antibodies each demonstrate ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

Lupus nephritis (LN) represents one of the most severe and life‐threatening manifestations of systemic lupus erythematosus (SLE), a chronic autoimmune disease marked by loss of self-tolerance and the ...